LABORATOIRES DOLIAGE DEVELOPPEMENT : revenue, balance sheet and financial ratios

LABORATOIRES DOLIAGE DEVELOPPEMENT is a French company founded 11 years ago, specialized in the sector Commerce de gros (commerce interentreprises) de produits pharmaceutiques. Based in PUTEAUX (92800), this company of category PME shows in 2023 a revenue of 1.8 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-05-09

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - LABORATOIRES DOLIAGE DEVELOPPEMENT (SIREN 804775807)
Indicator 2023 2022 2021 2016 2015
Revenue 1 781 436 € 1 838 882 € 1 312 034 € 300 004 € 251 233 €
Net income 278 385 € 71 687 € 93 863 € 71 500 € 57 687 €
EBITDA 325 262 € 88 416 € 138 975 € 17 832 € 57 962 €
Net margin 15.6% 3.9% 7.2% 23.8% 23.0%

Revenue and income statement

In 2023, LABORATOIRES DOLIAGE DEVELOPPEMENT achieves revenue of 1.8 M€. Over the period 2015-2023, the company shows strong growth with a CAGR (compound annual growth rate) of +27.7%. Slight decline of -3% vs 2022. After deducting consumption (1.0 M€), gross margin stands at 775 k€, i.e. a rate of 44%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 325 k€, representing 18.3% of revenue. Positive scissor effect: EBITDA margin improves by +13.5 pts, sign of improved operational efficiency. This high EBITDA margin provides strong self-financing capacity and resilience to uncertainties. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 278 k€, i.e. 15.6% of revenue. This profit can be retained or distributed to shareholders.

Revenue (2023) ?
Revenue
Definition
Total amount of sales of goods and services made by the company.
Formula
Sales of goods + Sold production

1 781 436 €

Gross margin (2023) ?
Gross margin
Definition
Difference between revenue and cost of goods sold.
Formula
Revenue - Cost of goods consumed

774 945 €

EBITDA (2023) ?
Gross Operating Surplus (EBITDA)
Definition
Resources generated by current operations, before depreciation and financial expenses.
Formula
Value added - Personnel expenses - Taxes
Interpretation
Positive = profitable activity

325 262 €

EBIT (2023) ?
EBIT (Operating Income)
Definition
Operating income, including depreciation and provisions.
Formula
EBITDA - Depreciation and provisions + Reversals

330 784 €

Net income (2023) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

278 385 €

EBITDA margin (2023) ?
EBITDA margin
Definition
Measures the company's operating profitability.
Formula
(EBE / CA) x 100
Interpretation
> 10% : Good profitability
5-10% : Average
< 5% : Low

18.3%

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 4%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 60%. This high autonomy means the company finances most of its assets through equity, a sign of strength. Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 0.1 years of cash flow to repay all financial debt. This short period demonstrates excellent debt sustainability. Cash flow represents 18.4% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment. This high level provides strong self-financing capacity.

Debt ratio (2023) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

3.71%

Financial autonomy (2023) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

59.738%

Cash flow / Revenue (2023) ?
Cash flow / Revenue
Definition
Self-financing capacity relative to revenue.
Formula
(CAF / CA) x 100
Interpretation
The higher the ratio, the more cash the company generates

18.425%

Repayment capacity (2023) ?
Repayment capacity
Definition
Number of years needed to repay debts with cash flow.
Formula
Financial debt / Cash flow
Interpretation
< 3 years : Excellent
3-5 years : Fair
> 5 years : Warning

0.098

Asset age ratio (2023) ?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Interpretation
< 50% : Recent assets
50-70% : Normal wear
> 70% : Aging assets

38.2%

Solvency indicators evolution
LABORATOIRES DOLIAGE DEVELOPPEMENT

Sector positioning

Debt ratio
3.71 2023
2021
2022
2023
Q1: 0.0
Med: 5.57
Q3: 50.77
Good -8 pts over 3 years

In 2023, the debt ratio of LABORATOIRES DOLIAGE DEVE... (3.71) ranks below the median of the sector. This ratio measures the weight of debt relative to equity. This controlled position reflects prudent management.

Financial autonomy
59.74% 2023
2021
2022
2023
Q1: 13.47%
Med: 38.42%
Q3: 58.45%
Excellent

In 2023, the financial autonomy of LABORATOIRES DOLIAGE DEVE... (59.7%) ranks in the top 25% of the sector. This ratio represents the share of equity in total financing. High autonomy reflects financial independence and ability to absorb shocks.

Repayment capacity
0.1 years 2023
2021
2022
2023
Q1: 0.0 years
Med: 0.0 years
Q3: 1.46 years
Average

In 2023, the repayment capacity of LABORATOIRES DOLIAGE DEVE... (0.10) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.

Liquidity ratios

The liquidity ratio (= Current assets / Current liabilities) stands at 173.50. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months. The interest coverage ratio (= EBIT / Interest expenses) is 2.2x. Financial charges are adequately covered by operations.

Liquidity ratio (2023) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

173.5

Interest coverage (2023) ?
Interest coverage
Definition
Ability to cover interest charges with operating income.
Formula
EBIT / Interest expenses
Interpretation
> 3 : Comfortable
1.5-3 : Acceptable
< 1.5 : Risk

2.212

Liquidity indicators evolution
LABORATOIRES DOLIAGE DEVELOPPEMENT

Sector positioning

Liquidity ratio
173.5 2023
2021
2022
2023
Q1: 133.58
Med: 205.53
Q3: 329.15
Average +14 pts over 3 years

In 2023, the liquidity ratio of LABORATOIRES DOLIAGE DEVE... (173.50) ranks below the median of the sector. This ratio measures the ability to cover short-term debt with current assets. An improvement would strengthen the competitive position.

Interest coverage
2.21x 2023
2021
2022
2023
Q1: 0.0x
Med: 0.29x
Q3: 6.06x
Good

In 2023, the interest coverage of LABORATOIRES DOLIAGE DEVE... (2.2x) ranks above the median of the sector. This ratio indicates how many times operating income covers interest expenses. This comfortable position offers an appreciable safety margin.

Working capital requirement (WCR) and payment terms

Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 68 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 87 days. Favorable situation: supplier credit is longer than customer credit by 19 days. Overall, WCR represents 30 days of revenue, i.e. 150 k€ to permanently finance. Over 2015-2023, WCR increased by +1664%, requiring additional financing.

Operating WCR (2023) ?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released
Positive = financing needed

149 641 €

Customer credit (2023) ?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good
45-60j : Average
> 60j : Long

68 j

Supplier credit (2023) ?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow

87 j

Inventory turnover (2023) ?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover

0 j

WCR in days of revenue (2023) ?
WCR in days of revenue
Definition
Expresses working capital requirement in days of revenue.
Formula
(Operating WCR / Revenue) x 360
Interpretation
The fewer days, the better the working capital management

30 j

WCR and payment terms evolution
LABORATOIRES DOLIAGE DEVELOPPEMENT

Positioning of LABORATOIRES DOLIAGE DEVELOPPEMENT in its sector

Comparison with sector Commerce de gros (commerce interentreprises) de produits pharmaceutiques

Valuation estimate

Based on 124 transactions of similar company sales (all years), the value of LABORATOIRES DOLIAGE DEVELOPPEMENT is estimated at 274 033 € (range 133 246€ - 928 439€). With an EBITDA of 325 262€, the sector multiple of 0.7x is applied. The price/revenue ratio is 0.21x (conservative valuation). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.

Estimated enterprise value 2023
124 transactions
133k€ 274k€ 928k€
274 033 € Range: 133 246€ - 928 439€
NAF 5 all-time

Valuation detail by method

Ajustez les pondérations selon votre analyse

EBITDA Multiple 50%
325 262 € × 0.7x
Estimation 228 947 €
108 231€ - 833 284€
Revenue Multiple 30%
1 781 436 € × 0.21x
Estimation 379 400 €
205 740€ - 1 149 210€
Net Income Multiple 20%
278 385 € × 0.8x
Estimation 228 698 €
87 044€ - 835 175€

Valuation evolution

How is this estimate calculated?

This estimate is based on the analysis of 124 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Commerce de gros (commerce interentreprises) de produits pharmaceutiques)

Compare LABORATOIRES DOLIAGE DEVELOPPEMENT with other companies in the same sector:

Voir toutes les statistiques du secteur Commerce de gros (commerce interentreprises) de produits pharmaceutiques

Frequently asked questions about LABORATOIRES DOLIAGE DEVELOPPEMENT

What is the revenue of LABORATOIRES DOLIAGE DEVELOPPEMENT ?

The revenue of LABORATOIRES DOLIAGE DEVELOPPEMENT in 2023 is 1.8 M€.

Is LABORATOIRES DOLIAGE DEVELOPPEMENT profitable?

Yes, LABORATOIRES DOLIAGE DEVELOPPEMENT generated a net profit of 278 k€ in 2023.

Where is the headquarters of LABORATOIRES DOLIAGE DEVELOPPEMENT ?

The headquarters of LABORATOIRES DOLIAGE DEVELOPPEMENT is located in PUTEAUX (92800), in the department Hauts-de-Seine.

Where to find the tax return of LABORATOIRES DOLIAGE DEVELOPPEMENT ?

The tax return of LABORATOIRES DOLIAGE DEVELOPPEMENT is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does LABORATOIRES DOLIAGE DEVELOPPEMENT operate?

LABORATOIRES DOLIAGE DEVELOPPEMENT operates in the sector Commerce de gros (commerce interentreprises) de produits pharmaceutiques (NAF code 46.46Z). See the 'Sector positioning' section above to compare the company with its competitors.